DexCom, Inc. CEO Kevin Sayer told investors during his presentation at the 2022 J.P. Morgan Healthcare Conference that clinical data from the company’s G7 continuous glucose monitoring system had exceeded all expectations. “The performance of this product is something I really never thought I would see in nearly 30 years in this business,” Sayer said.
The G7 CMG is 60% smaller than the G6, has less than a 30-minute “warm-up” period to acclimatize before getting sensor readings compared to about 2 hours for the G6,...